<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0702244866
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LYSTEDA 650 mg Tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TRANEXAMIC ACID
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        650
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        88.95
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="MIKART, INC." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            MIKART, INC.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 612]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Abdulrehman Algosaibi G.T.C.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Ferring Pharmaceuticals Inc./ USA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        B02AA02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Lysteda&trade;<br />(Tranexamic Acid) Tablets<br />Read the Patient Information that comes with<br />LYSTEDA before you start using the drug and each<br />time you get a refill. There may be new information.<br />This leaflet does not take the place of talking<br />with your healthcare provider about your medical<br />condition or your treatment<br />What is LYSTEDA?<br />LYSTEDA is a prescription medicine used to treat<br />your heavy monthly period (menstruation) when your<br />bleeding gets in the way of social, leisure and physical<br />activities. LYSTEDA does not contain any hormones.<br />On average, LYSTEDA has been shown to lower the<br />amount of blood lost during your monthly period<br />by about one‑third, but it is not meant to stop your<br />period. LYSTEDA is taken only during your period<br />and is not meant to treat pre-menstrual symptoms<br />(symptoms that occur before your bleeding starts).<br />LYSTEDA does not affect your fertility and cannot<br />be used as birth control. LYSTEDA does not protect<br />you against diseases that you may get if you have<br />unprotected sex. LYSTEDA has not been studied in<br />adolescents younger than 18 years of age.<br />LYSTEDA is not for women who have already gone<br />through menopause (post-menopausal).<br />Who should not take LYSTEDA?<br />Do not take LYSTEDA if you:<br />&bull; Are using a form of birth control that contains<br />estrogen and a progestin (like a birth control pill,<br />patch, or vaginal ring). Ask your healthcare provider<br />before taking LYSTEDA if you are not sure if your<br />birth control method contains estrogen and a<br />progestin.<br />&bull; Currently have a blood clot.<br />&bull; Have ever had a blood clot.<br />&bull; Have been told that you are at risk of having<br />a blood clot.<br />&bull; Are allergic to LYSTEDA or tranexamic acid.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Before taking LYSTEDA, tell your healthcare provider<br />about all of your medical conditions, including<br />whether:<br />&bull; You have ever had a blood clot or been told that<br />you are at risk of having a blood clot.<br />&bull; You are using a form of birth control that contains<br />estrogen and a progestin (like a birth control pill,<br />patch, or vaginal ring). Using hormonal birth control<br />along with LYSTEDA may increase your chance of<br />having a serious blood clot, stroke, or heart attack.<br />For this reason, do not use LYSTEDA if you use a<br />form of birth control that contains estrogen and a<br />progestin.<br />&bull; You are pregnant or think you may be pregnant.<br />&bull; You are breastfeeding or plan to breast‑feed.<br />LYSTEDA can pass into your milk. Talk to your<br />healthcare. provider about the best way to feed<br />your baby if you take LYSTEDA.<br />&bull; The time between the start of your periods is less<br />than 21 days or more than 35 days.<br />&bull; You have any other medical conditions.<br />Tell your healthcare provider about all the<br />medicines you take, including prescription and<br />over‑the-counter medicines, vitamins, and herbal<br />supplements. LYSTEDA and other medicines can<br />affect each other, causing side effects.<br />LYSTEDA can affect the way other medicines work<br />and other medicines can affect how LYSTEDA works.</p><p>Especially tell your healthcare provider if you<br />take:<br />&bull; Birth control pills or other hormonal birth control<br />&bull; Medicines used to help your blood form clots<br />&bull; Medicines used to break up blood clots<br />&bull; Any medicines to treat leukemia<br />Ask your healthcare provider if you are not sure if<br />your medicine is one that is described above.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Take LYSTEDA exactly as your healthcare provider<br />tells you.<br />&bull; Do not take LYSTEDA until your period has started.<br />&bull; Do not take LYSTEDA for more than 5 days in a<br />row.<br />&bull; Do not take LYSTEDA when you do not have your<br />period.<br />&bull; Once your period has started, take 2 tablets of<br />LYSTEDA three times per day (e.g., in the morning,<br />afternoon, and evening).<br />&bull; LYSTEDA tablets should be swallowed whole and<br />not chewed or broken apart.<br />&bull; LYSTEDA may be taken with or without food.<br />&bull; Do not take more than 6 tablets of LYSTEDA in<br />a day. If you take more than 6 tablets, call your<br />healthcare provider.<br />&bull; If you miss a dose, take it when you remember, and<br />then take your next dose at least six hours later. Do<br />not take more than two tablets at a time to make up<br />for missed doses.<br />&bull; If LYSTEDA does not help to lessen bleeding<br />with your periods after 2 cycles or seems to stop<br />working, talk to your healthcare provider.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>LYSTEDA can cause serious side effects, including:<br />&bull; Blood clots. You may have a higher risk of having<br />serious blood clots if you take LYSTEDA with:<br />-&nbsp;&nbsp; &nbsp;Medicines used to help your blood from clots<br />-&nbsp;&nbsp; &nbsp;Some medicines used to treat leukemia<br />&bull; Eye changes. Stop taking LYSTEDA and promptly<br />report any eye problems you have while taking<br />LYSTEDA. Your doctor will refer you to an eye<br />doctor who will examine your eyes.<br />&bull; Allergic reaction. If you have severe shortness<br />of breath and your throat feels tight, stop taking<br />LYSTEDA and get medical care right away.<br />The most common side effects of LYSTEDA include:<br />&bull; Headaches<br />&bull; Sinus and nasal problems<br />&bull; Back pain<br />&bull; Pain in your abdomen<br />&bull; Pain in your muscles or joints<br />&bull; Anemia<br />&bull; Fatigue<br />Tell your healthcare provider if you have any side<br />effect that bothers you or does not go away.<br />These are not all of the possible side effects of<br />LYSTEDA. For more information, ask your healthcare<br />provider or pharmacist.<br />If you notice a change in your usual bleeding pattern<br />that worries you, or your heavy bleeding continues,<br />contact your healthcare provider right away. This may&nbsp;be a sign of a more serious condition.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Store LYSTEDA below 30&deg;C.</p><p>Keep LYSTEDA and all medicines out of the reach<br />of children.<br />General information about LYSTEDA<br />Medicines are sometimes prescribed for conditions<br />that are not mentioned in Patient Information<br />Leaflets. Do not use LYSTEDA for a condition for<br />which it was not prescribed. Do not give LYSTEDA to<br />other people, even if they have the same symptoms<br />that you have. It may harm them.<br />This patient information leaflet summarizes the most<br />important information about LYSTEDA. If you would<br />like more information about LYSTEDA, talk with your<br />healthcare provider. You can ask your healthcare<br />provider or pharmacist for information about<br />LYSTEDA that is written for healthcare professionals.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Active ingredient: tranexamic acid<br />Inactive ingredients: microcrystalline cellulose,<br />colloidal silicon dioxide, pregelatinized corn<br />starch, povidone, hypromellose, stearic acid, and<br />magnesium stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                N/A
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Manufacturer:<br />Mikart, Inc. 2090 Marietta Blvd. Atlanta, GA 30318,<br />USA.<br />Marketing Authorization Holder:<br />Ferring Pharmaceuticals Inc., Parsippany, NJ 07054,&nbsp;USA.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                October 2013.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يصرف الدواء بوصفة طبية ويستعمل لعلاج نزيف الدورة الشهرية الحاد<br />)الحيض( وخاصة عندما يمنعك النزيف عن ممارسة أنشطتك الاجتماعية،<br />الترفيهية والجسدية.<br />لا تحتوي أقراص ليستيدا على أي هرمونات. تبين أن ليستيدا يقوم بتخفيض<br />كمية الدم المفقودة خلال فترة الدورة الشهرية بمعدل مقداره الثلث تقريباً، غير<br />وأن هذا لا يعني أنه يوقف الدورة الشهرية.<br />يتم تناول الدواء خلال فترة الدورة الشهرية فقط وهو غير مخصص لعلاج<br />أعراض ما قبل الحيض )الأعراض التي تحدث قبل أن يبدأ نزيف الدورة<br />الشهرية(. كما وأن ليستيدا لا يؤثر على معدل الخصوبة، ولا يمكن استعماله<br />كوسيلة لمنع الحمل.<br />كما أنه لا يحميكي من الأمراض التي قد تصابين بها نتيجة الممارسة الجنسية<br />من غير استعمال الوسائل الوقائية.<br />لم تتم دراسة ليستيدا على المراهقات اللواتي تقل أعمارهن عن 18 سنة.<br />لا يتم استعمال ليستيدا بعد انقطاع الحيض لدى النساء.<br />النساء اللواتي لا ينبغي عليهن تناول ليستيدا<br />لا تتناولي ليستيدا إذا كنت:<br />- تستخدمين أي وسيلة من وسائل منع الحمل التي تحتوي على الاستروجين<br />والبروجستين )مثل حبوب أو لزقات منع الحمل أو الحلقة المهبلية(.<br />استشيري مقدم الرعاية الصحية قبل استخدام ليستيدا في حال كنت غير<br />متأكدة فيما إذا كان أسلوب تحديد النسل الذي تستخدمينه يحتوي على<br />هرمون الاستروجين والبروجستين.<br />- تعانين حالياً من تجلط الدم.<br />- إذا سبق وتعرضت لتجلط الدم.<br />- تم إبلاغك بأنك عرضة للإصابة بتجلط الدم.<br />- إذا كان عندك حساسة من ليستيدا أو حمض الترانيكساميك.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>قبل استعمال ليستيدا، استشيري مقدم الرعاية الصحية حول جميع الظروف<br />الصحية الخاصة بك فيما إذا كنت:<br />- سبق وأن تعرضت الى جلطة دموية أو أنك عرضة للإصابة بجلطة دموية.<br />- تستخدمين وسيلة من وسائل منع الحمل التي تحتوي على الاستروجين<br />والبروجستين )مثل حبوب أو لزقات منع الحمل أو الحلقة المهبلية(. قد يزيد<br />تزامن استخدام وسائل منع الحمل الهرمونية مع ليستيدا من فرص تعرضك<br />للجلطة الدموية أو السكتة الدماغية، أو نوبة قلبية خطيرة. ولهذا السبب،<br />لا تستخدمي ليستيدا إذا كنت تستخدمين وسيلة من وسائل منع الحمل التي<br />تحتوي على الاستروجين والبروجستين.<br />- حاملاً أو تعتقدين أنك قد تكوني حاملاً.<br />- ترضعين رضاعة الطبيعية أو تخططين للرضاعة الطبيعية. يمكن أن ينتقل<br />ليستيدا الى حليبك. قومي باستشارة مقدم الرعاية الصحية حول أفضل<br />طريقة لتغذية طفلك إذا كنت تستخدمين ليستيدا.<br />- إذا كان الوقت بين بداية الدورات الشهرية لديك أقل من 21 يوماً أو أكثر<br />من 35 يوماً.<br />- تعانين من مشاكل طبية أخرى.<br />أخبري مقدم الرعاية الصحية عن جميع الأدوية التي تتناولينها، بما في ذلك<br />الأدوية التي تصرف بوصفات طبية والأدوية التي تصرف من دون وصفات<br />طبية والفيتامينات والمكملات العشبية.<br />يمكن أن يتداخل ليستيدا مع الأدوية الأخرى مما قد يسبب تأثيرات جانبية.<br />يمكن أن يؤثر ليستيدا على الطريقة التي تعمل بها الأدوية الأخرى، كما وأنه&nbsp;يمكن أن تؤثر الأدوية الأخرى على الطريقة التي يعمل بها ليستيدا.&nbsp;وبشكل خاص قومي باستشارة مقدم الرعاية الصحية إذا كنت تتناولين:<br />- حبوب منع الحمل أو غيرها من وسائل منع الحمل الهرمونية.<br />- الأدوية المستخدمة لعلاج الجلطات الدموية.<br />- الأدوية المستخدمة لتميع الجلطات الدموية.<br />- أي أدوية لعلاج سرطان الدم.<br />قومي باستشارة مقدم الرعاية الصحية إذا كنت غير متأكدة فيما إذا كان الدواء&nbsp;الذي تتناولينه هو أحد الأدوية المذكورة أعلاه.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="margin-right:40px">- قومي بتناول ليستيدا تماماً كما أخبرك مقدم الرعاية الصحية.<br />- لا تتناولي ليستيدا إلا عند بداية الدورة الشهرية.<br />- لا تتناولي ليستيدا لأكثر من خمسة أيام متتالية.<br />- لا تتناولي ليستيدا في حال عدم وجود الدورة الشهرية.<br />- عند بداية الدورة الشهرية، خذي قرصين ليستيدا ثلاث مرات يومياً )على<br />سبيل المثال في الصباح وبعد الظهر وفي المساء(.<br />- يجب بلع أقراص ليستيدا ولا يجب مضغها أو تفتيتها.<br />- يمكن أخذ ليستيدا مع أو بدون الطعام.<br />- لا تأخذي أكثر من ستة أقراص ليستيدا في اليوم. إذا تناولت أكثر من ستة<br />أقراص في يوم، يجب عليك الاتصال بمقدم الرعاية الصحية.<br />- إذا نسيت جرعة، عليك تناولها عندما تتذكرين، وبعدها تناولي الجرعة<br />التالية بعد ست ساعات على الأقل. لا تتناولي أكثر من قرصين في وقت<br />واحد لتعويض الجرعات التي نسيتها.<br />- إذا لم تساعد أقراص ليستيدا على تخفيف النزيف بعد دورتين شهريتين،<br />أو إذا تبنين لك أنها لا تعمل بشكل جيد، عندها عليك الاتصال مع مقدم&nbsp;الرعاية الصحية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>يمكن أن تسبب أقراص ليستيدا تأثيرات جانبية خطيرة، بما في ذلك:<br />&bull; تجلط الدم: يمكن أن تكون لديك احتمالية أكبر لإصابتك بتجلط الدم إذا كنت<br />تتناولين الأدوية التالية مع ليستيدا:<br />- الأدوية المستخدمة للمساعدة على منع الدم من التجلط.<br />- بعض الأدوية المستخدمة لعلاج سرطان الدم.<br />&bull; التغيرات في العين: في هذه الحالة توقفي عن تناول ليستيدا وابلغي مقدم<br />الرعاية الصحية فوراً عن أية مشاكل في العين التي عانيتها مع تناول<br />ليستيدا وسوف يقوم مقدم الرعاية الصحية بتحويلك الى طبيب عيون من<br />أجل فحص عينيك.<br />&bull; رد فعل تحسسي: إذا شعرت بضيق حاد في التنفس وأن هناك ضيق في<br />الحلق، توقفي فوراً عن تناول ليستيدا واحصلي على الرعاية الطبية فوراً.<br />الآثار الجانبية الأكثر شيوعاً لليستيدا ما يلي:<br />&bull; الصداع.<br />&bull; مشاكل الجيوب الأنفية والأنف.<br />&bull; آلام الظهر.<br />&bull; ألم في البطن.<br />&bull; ألم في العضلات أو المفاصل.<br />&bull; فقر الدم.<br />&bull; التعب.<br />أخبري طبيبك عن أية تأثيرات جانبية التي قد تزعجك أو تستمر في مضايقتك.<br />إن هذه ليست كل التأثيرات الجانبية المحتملة لليستيدا ولمزيد من المعلومات،<br />استشيري مقدم الرعاية الصحية أو الصيدلي. إذا لاحظت تغيراً في نمط نزيفك<br />المعتاد والذي قد يسبب لك قلقاً، أو إذا استمر نزيفك الحاد، اتصلي فوراً بمقدم<br />الرعاية الصحية.<br />إن هذه الحالة قد تكون إشارة على وجود حالة أكثر خطورة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحفظ ليستيدا تحت درجة حرارة 30 درجة مئوية.<br />إحفظي ليستيدا وجميع الأدوية بعيداً عن متناول الأطفال.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المكونات الفعالة: حمض الترانيكساميك.<br />المكونات غير الفعالة: سليلوز دقيق البلورات، ثاني أكسيد السليكون الغرواني،<br />نشويات دقيق الذرة، البوفيدون، هايبروميللوز، حمض الاستياريك وستيرات<br />المغنيسيوم.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>معلومات عامة عن ليستيدا<br />في بعض الأحيان توصف الأدوية لحالات لم ترد في نشرات معلومات<br />المريض. لا تستعملي ليستيدا لحالة غير موصوف لها. لا تعطي ليستيدا إلى<br />أشخاص آخرين، حتى لو كان لديهم نفس أعراضك، لأن هذا قد يضرهم.<br />تلخص هذه النشرة أهم المعلومات عن ليستيدا وإذا كنت ترغبين في المزيد من<br />المعلومات عن ليستيدا، استشيري مقدم الرعاية الصحية. كما ويمكنك ايضاً<br />أن تستشيري مقدم الرعاية الصحية أو الصيدلي للحصول على معلومات عن<br />ليستيدا والتي كتبت أصلاً للمتخصصين في الرعاية الصحية.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>المصنع: ميكارت المساهمة، 2090 مارييتا بوليفارد، أتلانتا، جي أيه<br />30318 ، الولايات المتحدة الأمريكية.<br />مالك حق التسويق: فيرينج فارماسوتيكالز المساهمة، بارسيباني، ان جي&nbsp;07054&nbsp;الولايات المتحدة الأمريكية.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            أكتوبر 2013 .
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                LYSTEDATM Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains 650 mg Tranexamic Acid.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablets
White oval-shaped tablets. Each tablet is debossed with the marking “FP650”.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of cyclic heavy menstrual bleeding<br />(Prior to prescribing LYSTEDA, exclude endometrial pathology that can be<br />associated with heavy menstrual bleeding)</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Recommended Dosage:<br />The recommended dose of LYSTEDA for women with normal renal function is two<br />650 mg tablets taken three times daily (3900 mg/day) for a maximum of 5 days<br />during monthly menstruation. LYSTEDA may be administered without regard to<br />meals. Tablets should be swallowed whole and not chewed or broken apart.<br />Renal Impairment:<br />In patients with renal impairment, the plasma concentration of tranexamic acid<br />increased as serum creatinine concertation increased. Dosage adjustment is needed<br />in patients with serum creatinine concentration higher than 1.4 mg/dL (Table 1).<br />Table 1. Dosage of LYSTEDA in Patients with Renal Impairment</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Thromboembolic Risk:
Do not prescribe LYSTEDA to women who are:
- Using combination hormonal contraception
- Known to have any of the following conditions:
1- Active thromboembolic disease (e.g., deep vein thrombosis, pulmonary
embolism, or cerebral thrombosis)
2- A history of thrombosis or thromboembolism, including retinal vein or artery
occlusion
3- An intrinsic risk of thrombosis or thromboembolism (e.g., thrombogenic
valvular disease, thrombogenic cardiac rhythm disease, or
hypercoagulopathy)
Venous and arterial thrombosis or thromboembolism, as well as cases of retinal
artery and retinal vein occlusions, have been reported with tranexamic acid.
Hypersensitivity to Tranexamic Acid:
Do not prescribe LYSTEDA to women with known hypersensitivity to tranexamic acid
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Thromboembolic Risk:<br />Concomitant Use of Hormonal Contraceptives<br />Combination hormonal contraceptives are known to increase the risk of venous<br />thromboembolism, as well as arterial thromboses such as stroke and myocardial<br />infarction. Because LYSTEDA is antifibrinolytic, the risk of venous thromboembolism,<br />as well as arterial thromboses such as stroke, may increase further when hormonal<br />contraceptives are administered with LYSTEDA. This is of particular concern in<br />women who are obese or smoke cigarettes, especially smokers over 35 years of age.<br />Women using hormonal contraception were excluded from the clinical trials<br />supporting the safety and efficacy of LYSTEDA, and there are no clinical trial data on<br />the risk of thrombotic events with the concomitant use of LYSTEDA with hormonal<br />contraceptives. However, there have been US postmarketing reports of venous and<br />arterial thrombotic events in women who have used LYSTEDA concomitantly with<br />combination hormonal contraceptives. For this reason, concomitant use of LYSTEDA<br />with combination hormonal contraceptives is contraindicated.<br />Factor IX Complex Concentrates or Anti-Inhibitor Coagulant Concentrates<br />LYSTEDA is not recommended for women taking either Factor IX complex<br />concentrates or anti-inhibitor coagulant concentrates because the risk of thrombosis<br />may be increased.<br />All-Trans Retinoic Acid (Oral Tretinoin)<br />Exercise caution when prescribing LYSTEDA to women with acute promyelocytic<br />leukemia taking all-trans retinoic acid for remission induction because of possible&nbsp;exacerbation of the procoagulant effect of all-trans retinoic acid.&nbsp;</p><p>Ocular Effects<br />Retinal venous and arterial occlusion has been reported in patients using tranexamic<br />acid. Patients should be instructed to report visual and ocular symptoms promptly. In<br />the event of such symptoms, patients should be instructed to discontinue LYSTEDA<br />immediately and should be referred to an ophthalmologist for a complete ophthalmic<br />evaluation, including dilated retinal examination, to exclude the possibility of retinal<br />venous or arterial occlusion.<br />Severe Allergic Reaction:<br />A case of severe allergic reaction to LYSTEDA was reported in the clinical trials,<br />involving a subject who experienced dyspnea, tightening of her throat, and facial<br />flushing that required emergency medical treatment. A case of anaphylactic shock<br />has also been reported in the literature, involving a patient who received an<br />intravenous bolus of tranexamic acid.<br />Subarachnoid Hemorrhage:<br />Cerebral edema and cerebral infarction may be caused by use of LYSTEDA in<br />women with subarachnoid hemorrhage.<br />Ligneous Conjunctivitis:<br />Ligneous conjunctivitis has been reported in patients taking tranexamic acid. The&nbsp;conjunctivitis resolved following cessation of the drug.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not drug-drug interaction studies were conducted with LYSTEDA&nbsp;</p><p>Hormonal Contraceptives:<br />Because LYSTEDA is antifibrinolytic, concomitant use of hormonal contraception and<br />LYSTEDA may further exacerbate the increased thrombotic risk associated with<br />combination hormonal contraceptives. For this reason, concomitant use of LYSTEDA<br />with combination hormonal contraceptives is contraindicated.<br />Tissue Plasminogen Activators:<br />Concomitant therapy with tissue plasminogen activators may decrease the efficacy of<br />both LYSTEDA and tissue plasminogen activators. Therefore, exercise caution if a<br />women taking LYSTEDA therapy requires tissue plasminogen activators.<br />Factor IX Complex Concentrates or Anti-Inhibitor Coagulant Concentrates:<br />LYSTEDA is not recommended for women taking either Factor IX complex<br />concentrates or anti-inhibitor coagulant concentrates because the risk of thrombosis<br />may be increased.<br />All-Trans Retinoic Acid (Oral Tretinoin):<br />In a study involving 28 patients with acute promyelocytic leukemia who were given<br />either orally administered all-trans retinoic acid plus intravenously administered<br />tranexamic acid, all-trans retinoic acid plus chemotherapy, or all-trans retinoic acid<br />plus tranexamic acid plus chemotherapy, all 4 patients who were given all-trans<br />retinoic acid plus tranexamic acid died, with 3 of the 4 deaths due to thrombotic<br />complications. It appears that the procoagulant effect of all-trans retinoic acid may be<br />exacerbated by concomitant use of tranexamic acid. Therefore, exercise caution<br />when prescribing LYSTEDA to women with acute promyelocytic leukemia taking all&nbsp;trans retinoic acid for remission induction because of possible exacerbation of the<br />procoagulant effect of all-trans retinoic acid.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy (Category B) and Fertility:<br />LYSTEDA is not indicated for use in pregnant women. Reproduction studies have<br />been performed in mice, rats and rabbits and have revealed no evidence of impaired<br />fertility or harm to the fetus due to tranexamic acid. However, tranexamic acid is<br />known to cross the placenta and appears in cord blood at concentrations<br />approximately equal to the maternal concentration. There are no adequate and wellcontrolled<br />studies in pregnant women.<br />An embryo-fetal developmental toxicity study in rats and a perinatal developmental<br />toxicity study in rats were conducted using tranexamic acid. No adverse effects were<br />observed in either study at doses up to 4 times the recommended human oral dose<br />of 3900 mg/day based on mg/m2 (actual animal dose 1500 mg/kg/day).<br />Lactation:<br />Tranexamic acid is present in the mother&rsquo;s milk at a concentration of about one<br />hundredth of the corresponding serum concentration. LYSTEDA should be used<br />during lactation only if clearly needed.<br />Paediatric Use:<br />LYSTEDA is indicated for women of reproductive age and is not intended for use in<br />premenarcheal girls. Based on a pharmacokinetic study in 20 adolescent females, 12<br />to 16 years of age, no dose adjustment is needed in the adolescent population.<br />Geriatric Use:<br />LYSTEDA is indicated for women of reproductive age and is not intended for use by<br />postmenopausal women.<br />Renal Impairment:<br />The effect of renal impairment on the pharmacokinetics of LYSTEDA has not been<br />studied. Because tranexamic acid is primarily eliminated via the kidneys by<br />glomerular filtration with more than 95% excreted as unchanged in urine, dosage<br />adjustment in patient with renal impairment is needed.<br />Hepatic Impairment:<br />The effect of hepatic impairment on the pharmacokinetics of LYSTEDA has not been<br />studied. Because only a small fraction of the drug is metabolized, dosage adjustment&nbsp;in patients with hepatic impairment is not needed.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>LYSTEDA has no or negligible influence on the ability to drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clinical Trial Experience:<br />Because clinical trials are conducted under widely varying conditions, adverse<br />reaction rates observed in the clinical trials of a drug cannot be directly compared to<br />the rates in the clinical trials of another drug and may not reflect the rates observed in&nbsp;clinical practice.</p><p>Short-Term Studies<br />The efficacy and safety of LYSTEDA in the treatment of heavy menstrual bleeding<br />(HMB) was demonstrated in one 3-cycle treatment and one 6-cycle treatment,<br />randomized, double-blind, placebo controlled studies. In these studies, HMB was<br />defined in these studies as an average menstrual blood loss of &ge; 80 mL as assessed<br />by alkaline hematin analysis of collected sanitary products over two baseline<br />menstrual cycles. Subjects were 18 to 49 years of age with a mean age of<br />approximately 40 years, had cyclic menses every 21-35 days, and a BMI of<br />approximately 32 kg/m2. On average, subjects had an HMB history of approximately<br />10 years and 40% had fibroids as determined by transvaginal ultrasound.<br />Approximately 70% were Caucasian, 25% were Black, and 5% were Asian, Native<br />American, Pacific Islander, or Other. Seven percent (7%) of all subjects were of<br />Hispanic origin. Women using hormonal contraception were excluded from the trials.<br />The primary outcome measure was menstrual blood loss (MBL), measured using the<br />alkaline hematin method. The endpoint was the change from baseline in MBL,<br />calculated by subtracting the mean MBL during treatment from the mean<br />pretreatment MBL.<br />The key secondary outcome measures were based on specific questions concerning<br />limitations in social or leisure activities (LSLA) and limitations in physical activities<br />(LPA). Large stains (soiling beyond the undergarment) were also included as a key<br />secondary outcome measure.<br />- Three-Cycle Treatment Study<br />This study compared the effects of two doses of LYSTEDA (1950 mg and<br />3900 mg given daily for up to 5 days during each menstrual period) versus<br />placebo on MBL over a 3-cycle treatment duration. Of the 294 evaluable<br />subjects, 115 LYSTEDA 1950 mg/day subjects, 112 LYSTEDA 3900 mg/day<br />subjects and 67 placebo subjects took at least one dose of study drug and&nbsp;had post-treatment data available.</p><p>Results are shown in Table 2. MBL was statistically significantly reduced in<br />patients treated with 3900 mg/day LYSTEDA compared to placebo. Study<br />success also required achieving a reduction in MBL that was determined to be<br />clinically meaningful to the subjects. The 1950 mg/day LYSTEDA dose did not&nbsp;meet the criteria for success.&nbsp;</p><p>&nbsp;</p><p>LYSTEDA also statistically significantly reduced limitations on social, leisure,<br />and physical activities in the 3900 mg/day dose group compared to placebo<br />(see Table 3). No statistically significant treatment difference was observed in<br />response rates on the number of large stains&nbsp;</p><p>&nbsp;</p><p>a Response categories 1=not at all limited; 2=slightly limited; 3=moderately limited; 4=quite a bit limited;<br />5=extremely limited<br />b Positive means reflect an improvement from baseline<br />c p-value &lt;0.05 versus placebo<br />d Responders are defined as subjects who experienced a reduction from baseline in frequency of large<br />stains<br />e Non-significant difference versus placebo<br />The rates of discontinuation due to adverse events during this clinical trial were<br />comparable between LYSTEDA and placebo. In this study, the rate in the 3900 mg<br />LYSTEDA dose group was 0.8% as compared to 1.4% in the placebo group.<br />- Six-Cycle Treatment Study<br />This study compared the effects of LYSTEDA 3900 mg/day given daily for up<br />to 5 days during each menstrual period versus placebo on MBL over a 6-cycle<br />treatment duration. Of the 187 evaluable subjects, 115 LYSTEDA subjects<br />and 72 placebo subjects took at least one dose of study drug and had posttreatment<br />data available<br />Results are shown in Table 4. MBL was statistically significantly reduced in<br />patients treated with 3900 mg/day LYSTEDA compared to placebo. Study<br />success also required achieving a reduction in MBL that was determined to be&nbsp;clinically meaningful to the subjects.</p><p>&nbsp;</p><p>Limitations on social, leisure, and physical activities were also statistically<br />significantly reduced in the LYSTEDA group compared to placebo (see Table<br />5). No statistically significant treatment difference was observed in response&nbsp;rates on the number of large stains.&nbsp;</p><p>&nbsp;</p><p>a Response categories 1=not at all limited; 2=slightly limited; 3=moderately limited; 4=quite a bit limited;<br />5=extremely limited<br />b Positive means reflect an improvement from baseline<br />c p-value &lt;0.05 versus placebo<br />d Responders are defined as subjects who experienced a reduction from baseline in frequency of large<br />stains<br />e Non-significant difference versus placebo<br />The rates of discontinuation due to adverse events during this clinical trial were<br />comparable between LYSTEDA and placebo. In this study, the rate in the LYSTEDA<br />group was 2.4% as compared to 4.1% in the placebo group. Across the studies, the<br />combined exposure to 3900 mg/day LYSTEDA was 947 cycles and the average<br />duration of use was 3.4 days per cycle.<br />MBL Results over Time<br />The efficacy of LYSTEDA 3900 mg/day over 3 menstrual cycles and over 6<br />menstrual cycles was demonstrated versus placebo in the double-blind, placebocontrolled<br />efficacy studies (see Figure 1). The change in MBL from baseline was<br />similar across all post-baseline treatment cycles.<br />&nbsp;</p><p>A list of adverse events occurring in &ge; 5% of subjects and more frequently in<br />LYSTEDA treated subjects receiving 3900 mg/day compared to placebo is provided&nbsp;in Table 6.&nbsp;</p><p>&nbsp;</p><p>a Includes headache and tension headache<br />b Nasal and sinus symptoms include nasal, respiratory tract and sinus congestion, sinusitis, acute<br />sinusitis, sinus headache, allergic sinusitis and sinus pain, and multiple allergies and seasonal allergies<br />c Abdominal pain includes abdominal tenderness and discomfort<br />d Musculoskeletal pain includes musculoskeletal discomfort and myalgia<br />e Arthralgia includes joint stiffness and swelling<br />Long-Term Studies<br />Long-term safety of LYSTEDA was studied in two open-label studies. In one study,<br />subjects with physician-diagnosed heavy menstrual bleeding (not using the alkaline<br />hematin methodology) were treated with 3900 mg/day for up to 5 days during each<br />menstrual period for up to 27 menstrual cycles. A total of 781 subjects were enrolled<br />and 239 completed the study through 27 menstrual cycles. A total of 12.4% of the<br />subjects withdrew due to adverse events. Women using hormonal contraception<br />were excluded from the study. The total exposure in this study to 3900 mg/day<br />LYSTEDA was 10,213 cycles. The average duration of LYSTEDA use was 2.9 days<br />per cycle.<br />A long-term open-label extension study of subjects from the two short-term efficacy<br />studies was also conducted in which subjects were treated with 3900 mg/day for up<br />to 5 days during each menstrual period for up to 9 menstrual cycles. A total of 288<br />subjects were enrolled and 196 subjects completed the study through 9 menstrual<br />cycles. A total of 2.1% of the subjects withdrew due to adverse events. The total<br />exposure to 3900 mg/day LYSTEDA in this study was 1,956 cycles. The average<br />duration of LYSTEDA use was 3.5 days per cycle.<br />The types and severity of adverse events in these two long-term open-label trials<br />were similar to those observed in the double-blind, placebo-controlled studies&nbsp;although the percentage of subjects reporting them was greater in the 27-month<br />study, most likely because of the longer study duration.<br />A case of severe allergic reaction to LYSTEDA was reported in the extension trial,<br />involving a subject on her fourth cycle of treatment, who experienced dyspnea,<br />tightening of her throat, and facial flushing that required emergency medical<br />treatment.<br />Post-Marketing Experience:<br />The following adverse reactions have been identified from postmarketing experience<br />with tranexamic acid. Because these reactions are reported voluntarily from a<br />population of uncertain size, it is not always possible to reliably estimate their<br />frequency or establish a causal relationship to drug exposure.<br />Based on US and worldwide postmarketing reports, the following have been reported<br />in patients receiving tranexamic acid for various indications:<br />- Nausea, vomiting and diarrhea<br />- Allergic skin reactions<br />- Anaphylactic shock and anaphylactoid reactions<br />- Thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism,<br />cerebral thrombosis, acute renal cortical necrosis, and central retinal artery and&nbsp;vein obstruction); cases have been associated with concomitant use of<br />combination hormonal contraceptives</p><p>- Impaired color vision and other visual disturbances</p><p>- Dizziness</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no known cases of intentional overdose with LYSTEDA and no subjects in<br />the clinical program took more than 2 times the prescribed amount of LYSTEDA in a<br />24-hour period (&gt;7800 mg/day). However, cases of overdose of tranexamic acid have<br />been reported. Based on these reports, symptoms of overdose may include<br />gastrointestinal (nausea, vomiting, diarrhea); hypotensive (e.g., orthostatic<br />symptoms); thromboembolic (arterial, venous, embolic); visual impairment, mental<br />status changes; myoclonus; or rash. No specific information is available on the<br />treatment of overdose with LYSTEDA. In the event of overdose, employ the usual<br />supportive measures (e.g., clinical monitoring and supportive therapy) as dictated by&nbsp;the patient&rsquo;s clinical status.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Blood and Blood Forming Organs, Antihemorrhagics,<br />Antifibrinolytics, Amino Acids<br />ATC code: B02AA02<br />Tranexamic acid, at in vitro concentrations of 25 &ndash; 100 M, reduces by 20 &ndash; 60% the<br />maximal rate of plasmin lysis of fibrin catalyzed by tissue plasminogen activator<br />(tPA).<br />Elevated concentrations of endometrial, uterine, and menstrual blood tPA are<br />observed in women with heavy menstrual bleeding (HMB) compared to women with<br />normal menstrual blood loss. The effect of tranexamic acid on lowering endometrial<br />tPA activity and menstrual fluid fibrinolysis is observed in women with HMB receiving&nbsp;tranexamic acid total oral doses of 2-3 g/day for 5 days.</p><p>In healthy subjects, tranexamic acid at blood concentrations less than 10 mg/mL has<br />no effect on the platelet count, the coagulation time or various coagulation factors in<br />whole blood or citrated blood. Tranexamic acid, however, at blood concentrations of<br />1 and 10 mg/mL prolongs the thrombin time.<br />Cardiac Electrophysiology<br />The effect of LYSTEDA on QT interval was evaluated in a randomized, single-dose,<br />4-way crossover study in 48 healthy females aged 18 to 49 years. Subjects received<br />(1) LYSTEDA 1300 mg (two 650 mg tablets), (2) LYSTEDA 3900 mg (six 650 mg<br />tablets; three times the recommended single dose), (3) moxifloxacin 400 mg, and (4)<br />placebo. There was no significant increase in the corrected QT interval at any time up<br />to 24 hours after the administration of either dose of LYSTEDA. Moxifloxacin, the<br />active control, was associated with a maximum 14.11 msec mean increase in<br />corrected QT interval (moxifloxacin &ndash; placebo) at 3 hours after administration.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption:<br />After a single oral administration of two 650 mg tablets of LYSTEDA, the peak<br />plasma concentration (Cmax) occurred at approximately 3 hours (Tmax). The absolute<br />bioavailability of LYSTEDA in women aged 18-49 is approximately 45%. Following<br />multiple oral doses (two 650 mg tablets three times daily) administration of LYSTEDA<br />for 5 days, the mean Cmax increased by approximately 19% and the mean area under<br />the plasma concentration-time curve (AUC) remained unchanged, compared to a<br />single oral dose administration (two 650 mg tablets). Plasma concentrations reached<br />steady state at the 5th dose of LYSTEDA on Day 2.<br />The mean plasma pharmacokinetic parameters of tranexamic acid determined in 19<br />healthy women following a single (two 650 mg tablets) and multiple (two 650 mg<br />tablets three times daily for 5 days) oral dose of LYSTEDA are shown in Table 7.<br />Table 7. Mean (CV%) Pharmacokinetic parameters following a single (two 650 mg tablets) and<br />multiple oral dose (two 650 mg tablets three times daily for 5 days) administration of LYSTEDA in&nbsp;19 healthy women under fasting conditions</p><p>Cmax = Maximum concentration<br />AUCtldc = Area under the drug concentration curve from time 0 to time of last determinable concentration<br />AUCinf = Area under the drug concentration curve from time 0 to infinity<br />Tmax = Time to maximum concentration<br />T1/2 = Terminal elimination half-life<br />aAUC0-tau (mcg.h/mL) = Area under the drug concentration curve from time 0 to 8 hours<br />bData preseted as median (range)&nbsp;Effect of food: LYSTEDA may be administered without regard to meals. A single<br />dose administration (two 650 mg tablets) of LYSTEDA with food increased both Cmax<br />and AUC by 7% and 16% respectively.<br />Distribution:<br />Tranexamic acid is 3% bound to plasma proteins with no apparent binding to<br />albumin. Tranexamic acid is distributed with an initial volume of distribution of 0.18<br />L/kg and steady-state apparent volume of distribution of 0.39 L/kg.<br />Tranexamic acid crosses the placenta. The concentration in cord blood after an<br />intravenous injection of 10 mg/kg to pregnant women is about 30 mg/L, as high as in<br />the maternal blood.<br />Tranexamic acid concentration in cerebrospinal fluid is about one tenth of the plasma<br />concentration.<br />The drug passes into the aqueous humor of the eye achieving a concentration of<br />approximately one tenth of plasma concentrations.<br />Metabolism:<br />A small fraction of the tranexamic acid is metabolized.<br />Excretion:<br />Tranexamic acid is eliminated by urinary excretion primarily via glomerular filtration<br />with more than 95% of the dose excreted unchanged. Excretion of tranexamic acid is<br />about 90% at 24 hours after intravenous administration of 10 mg/kg. Most elimination<br />post intravenous administration occurred during the first 10 hours, giving an apparent<br />elimination half-life of approximately 2 hours. The mean terminal half-life of<br />LYSTEDA is approximately 11 hours. Plasma clearance of tranexamic acid is 110-&nbsp;116 mL/min.&nbsp;</p><p>Specific Populations<br />Pregnancy (Category B)<br />LYSTEDA is not indicated for use in pregnant women. Tranexamic acid is known to<br />cross the placenta and appears in cord blood at concentrations approximately equal<br />to maternal concentration. There are no adequate and well-controlled studies in<br />pregnant women<br />Nursing Mothers<br />Tranexamic acid is present in the mother&rsquo;s milk at a concentration of about one<br />hundredth of the corresponding serum concentrations. LYSTEDA should be used<br />during lactation only if clearly needed.<br />Pediatric Use<br />LYSTEDA is indicated for women of reproductive age and is not intended for use in<br />premenarcheal girls. In a randomized, single dose, two-way crossover study of two<br />dose levels (650 mg and 1,300 mg [two 650 mg tablets]), pharmacokinetics of<br />tranexamic acid was evaluated in 20 female adolescents (12 to 16 years of age) with<br />heavy menstrual bleeding. The Cmax and AUC values after a single oral dose of 650<br />mg in the adolescent females were 32 &ndash; 36% less than those after a single oral dose<br />of 1,300 mg in the adolescent females. The Cmax and AUC values after a single oral<br />dose of 1300 mg in the adolescent females were 20 &ndash; 25% less than those in the&nbsp;adult females given the same dose in a separate study.</p><p>Geriatric Use<br />LYSTEDA is indicated for women of reproductive age and is not intended for use by<br />postmenopausal women.<br />Renal Impairment<br />The effect of renal impairment on the disposition of LYSTEDA has not been<br />evaluated. Urinary excretion following a single intravenous injection of tranexamic<br />acid declines as renal function decreases. Following a single 10 mg/kg intravenous<br />injection of tranexamic acid in 28 patients, the 24-hour urinary fractions of tranexamic<br />acid with serum creatinine concentrations 1.4 &ndash; 2.8, 2.8 &ndash; 5.7, and greater than<br />5.7 mg/dL were 51, 39, and 19%, respectively. The 24-hour tranexamic acid plasma<br />concentrations for these patients demonstrated a direct relationship to the degree of<br />renal impairment. Therefore, dose adjustment is needed in patients with renal<br />impairment.<br />Hepatic Impairment<br />The effect of hepatic impairment on the disposition of LYSTEDA has not been<br />evaluated. One percent and 0.5 percent of an oral dose are excreted as a<br />dicarboxylic acid and acetylated metabolite, respectively. Because only a small<br />fraction of the drug is metabolized, no dose adjustment is needed in patients with&nbsp;hepatic impairment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Carcinogenesis, Mutagenesis, Impairment of Fertility<br />Carcinogenesis<br />Carcinogenicity studies with tranexamic acid in male mice at doses as high as 6<br />times the recommended human dose of 3900 mg/day showed an increased<br />incidence of leukemia which may have been related to treatment. Female mice were<br />not included in this experiment.<br />The dose multiple referenced above is based on body surface area (mg/m2). Actual<br />daily dose in mice was up to 5000 mg/kg/day in food.<br />Hyperplasia of the biliary tract and cholangioma and adenocarcinoma of the<br />intrahepatic biliary system have been reported in one strain of rats after dietary<br />administration of doses exceeding the maximum tolerated dose for 22 months.<br />Hyperplastic, but not neoplastic, lesions were reported at lower doses. Subsequent<br />long-term dietary administration studies in a different strain of rat, each with an<br />exposure level equal to the maximum level employed in the earlier experiment, have<br />failed to show such hyperplastic/neoplastic changes in the liver.<br />Mutagenesis<br />Tranexamic acid was neither mutagenic nor clastogenic in the in vitro Bacterial<br />Reverse Mutation Assay (Ames test), in vitro chromosome aberration test in Chinese<br />hamster cells, and in in vivo chromosome aberration tests in mice and rats.<br />Impairment of Fertility<br />Reproductive studies performed in mice, rats and rabbits have not revealed any<br />evidence of impaired fertility or adverse effects on the fetus due to tranexamic acid.&nbsp;In a rat embryo-fetal developmental toxicity study, tranexamic acid had no adverse<br />effects on embryofetal development when administered during the period of<br />organogenesis (from gestation days 6 through 17) at doses 1, 2 and 4 times the&nbsp;recommended human oral dose of 3900 mg/day. In a perinatal-postnatal study in<br />rats, tranexamic acid had no adverse effects on pup viability, growth or development<br />when administered from gestation day 6 through postnatal day 20 at doses 1, 2 and<br />4 times the recommended human oral dose of 3900 mg/day.<br />The dose multiples referenced above are based on body surface area (mg/m2).<br />Actual daily doses in rats were 300, 750 or 1500 mg/kg/day.<br />Animal Toxicology and/or Pharmacology<br />Ocular Effects<br />In a 9-month toxicology study, dogs were administered tranexamic acid in food at<br />doses of 0, 200, 600, or 1200 mg/kg/day. These doses are approximately 2, 5, and 6<br />times, respectively, the recommended human oral dose of 3900 mg/day based on<br />AUC. At 6 times the human dose, some dogs developed reversible reddening and<br />gelatinous discharge from the eyes. Ophthalmologic examination revealed reversible<br />changes in the nictitating membrane/conjunctiva. In some female dogs, the presence<br />of inflammatory exudate over the bulbar conjunctival mucosa was observed.<br />Histopathological examinations did not reveal any retinal alteration. No adverse<br />effects were observed at 5 times the human dose.<br />In other studies, focal areas of retinal degeneration were observed in cats, dogs and<br />rats following oral or intravenous tranexamic acid doses at 6-40 times the<br />recommended usual human dose based on mg/m2 (actual animal doses between&nbsp;250-1600 mg/kg/day).&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><br />Microcrystalline Cellulose NF, Colloidal Silicon Dioxide, Pregelatinized Corn Starch,&nbsp;Povidone, Hypromellose, Stearic Acid and Magnesium Stearate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                48 Months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store at room temperature 25&deg; C (77&deg; F); excursions permitted to 15-30&deg; C (59-86&deg; F).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>LYSTEDA (tranexamic acid) tablets are provided as white oval-shaped tablets. Each&nbsp;tablet is debossed with the marking &ldquo;FP650&rdquo; and are supplied as:</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special precautions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                FERRING Pharmaceuticals Inc. / USA
NJ 07054, Parsippany
USA
8. Marketing authorisation number
78793.00.00 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                October 2013
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>